Indhira Pérez‐Medrano
A5085347360- Liver Diseases and Immunity
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Organ Transplantation Techniques and Outcomes
- Hepatitis Viruses Studies and Epidemiology
- Transplantation: Methods and Outcomes
- Renal Transplantation Outcomes and Treatments
- IgG4-Related and Inflammatory Diseases
- SARS-CoV-2 and COVID-19 Research
- Gallbladder and Bile Duct Disorders
- Drug Transport and Resistance Mechanisms
- Pediatric Hepatobiliary Diseases and Treatments
- Drug-Induced Hepatotoxicity and Protection
- Hepatitis B Virus Studies
Complexo Hospitalario Universitario A Coruña
2024-2025
Complejo Hospitalario de Pontevedra
2021-2025
Sofia University "St. Kliment Ohridski"
2015
Background and Aims: In patients with non-severe acute or chronic autoimmune hepatitis (AIH) without cirrhosis, clinical practice guidelines recommend indistinct use of prednisone budesonide. However, budesonide is infrequently used in practice. We aimed to describe its compare efficacy safety as first-line options. Approach Results: This was a retrospective, multicenter study 105 naive AIH treated the drug. The control group included 276 prednisone. Efficacy assessed using logistic...
Abstract Background and Aims Small series suggest that rituximab could be effective as treatment for autoimmune hepatitis (AIH), although data are scarce. We aimed to evaluate the efficacy safety of in different cohorts patients with AIH. Methods Multicentre retrospective analysis 35 AIH its variant forms treated included ColHai registry between 2015 2023. Results Most were female (83%), 10 (29%) had cirrhosis four (11.4%) Indication follows: 14(40%) refractory AIH, 19(54%) concomitant or...
The landscape in primary biliary cholangitis (PBC) has changed with the advent of second-line treatments. However, use obeticholic acid (OCA) and fibrates PBC-related cirrhosis is challenging. We assessed impact receiving a therapy as risk factor for decompensated real-world population PBC, identify predictive factors these patients.
INTRODUCTION: Obeticholic acid (OCA) and fibrates therapy results in biochemical improvement placebo-controlled trials patients with primary biliary cholangitis insufficient response to ursodeoxycholic acid. There is scarce information outside of clinical trials. Therefore, we have assessed the effectiveness adverse events these treatments. METHODS: Data from included ColHai registry treated OCA, fibrates, or both were recorded during a year, as well treatment discontinuation. RESULTS:...
The management of autoimmune hepatitis (AIH) is based on immunosuppressive agents that may increase the risk opportunistic infections (OI). However, data their prevalence and incidence are lacking, which explain absence specific recommendations. To characterise screening, occurrence treatment OI in patients with AIH. Retrospective multicentre study conducted 20 Spanish centres involving AIH treated corticosteroid-based regimens. From 2000 to 2023, 2893 were treated. Latent Tuberculosis...
Different patterns of liver injury have been reported in association with the SARS-CoV-2 vaccines. The aim this study was to describe a nationwide cohort patients SARS CoV-2 vaccine-induced injury, focusing on treatment and evolution after further booster administration. multicentre, retrospective-prospective study, including subjects who developed abnormal tests within 90 days administration vaccination. 47 cases were collected: 17 prime dose 30 booster. Age 57 years, (63.8%) female, 7...